Inhibition of the multiplication of Mycobacterium leprae by vaccination with a recombinant M. bovis BCG strain that secretes major membrane protein II in mice.
The ability of a recombinant Mycobacterium bovis BCG strain that secretes major membrane protein II (MMP-II) of Mycobacterium leprae (BCG-SM) to confer protection against leprosy was evaluated by use of a mouse footpad model. C57BL/6J mice intradermally inoculated with BCG-SM produced splenic T cells which secreted significant amounts of gamma interferon (IFN-gamma) in response to either the recombinant MMP-II, the M. leprae-derived membrane fraction, or the BCG-derived cytosolic fraction in vitro more efficiently than those from the mice infected with the vector control BCG strain (BCG-pMV, a BCG strain containing pMV-261). A higher percentage of CD8(+) T cells obtained from BCG-SM-inoculated mice than those obtained from BCG-pMV-inoculated mice produced intracellular IFN-gamma on restimulation with the M. leprae antigens. BCG-SM inhibited the multiplication of M. leprae in the footpads of C57BL/6J mice more efficiently than BCG-pMV. These results indicate that a BCG strain that secretes MMP-II could be a better vaccine candidate for leprosy.
Maeda
Y
Y
Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo 189-0002, Japan.
Tamura
T
T
Matsuoka
M
M
Makino
M
M
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics; D001500:BCG Vaccine / Q000235:genetics* / Q000276:immunology*; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology; D006801:Humans; D007918:Leprosy / Q000276:immunology / Q000517:prevention & control; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009166:Mycobacterium leprae / Q000235:genetics / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D001428:Bacterial Vaccines; D008565:Membrane Proteins; D014614:Vaccines, Synthetic; C500901:major membrane protein II, Mycobacterium leprae
Int J Tuberc Lung Dis. 2008 Dec;12(12):1376-9
19017445
Indian J Dermatol Venereol Leprol. 2007 Mar-Apr;73(2):86-93
17456912
Int J Lepr Other Mycobact Dis. 1999 Dec;67(4 Suppl):S59-62
10700939
Vaccine. 2001 Feb 28;19(15-16):1906-10
11228360
Int J Lepr Other Mycobact Dis. 2000 Dec;68(4):434-43
11332286
Infect Immun. 1994 Oct;62(10):4250-5
7927681
Nihon Rai Gakkai Zasshi. 1994 Jul;63(2):47-50
7844062
Lancet. 2006 Apr 8;367(9517):1173-80
16616560
Lepr Rev. 1993 Dec;64(4):302-11
8127216
Lancet. 1996 Jul 6;348(9019):17-24
8691924
Infect Immun. 2006 Nov;74(11):6264-71
17057093
J Invest Dermatol. 1994 Jun;102(6):828-32
8006444
Int J Lepr Other Mycobact Dis. 1987 Dec;55(4 Suppl):889-95
3325583
Infect Immun. 2003 Mar;71(3):1596-8
12595485
Int J Lepr Other Mycobact Dis. 1968 Jan-Mar;36(1):78-82
4869698
J Exp Med. 1990 Jun 1;171(6):2011-24
1972178
Vaccine. 2007 Jan 2;25(1):14-8
16959383
Mol Microbiol. 1996 Apr;20(2):283-93
8733228
Lancet Infect Dis. 2006 Mar;6(3):162-70
16500597
Int J Lepr Other Mycobact Dis. 1983 Dec;51(4):519-23
6368416
Lancet. 1992 Mar 14;339(8794):636-9
1347338
Infect Immun. 2005 May;73(5):2744-50
15845477
Lancet. 1992 Feb 22;339(8791):446-50
1346818
Int J Lepr Other Mycobact Dis. 2002 Sep;70(3):182-90
12483966
Wkly Epidemiol Rec. 2008 Aug 15;83(33):293-300
18705152
Lepr Rev. 2005 Jun;76(2):127-43
16038246